At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
09887 LEADS BIOLABS-B
Noon Closed 03-18 12:05:00
62.950
+0.050
+0.08%
High65.100Low61.950Vol80.20K
Open62.900D1 Closing62.900Amplitude5.01%
Mkt Cap12.53BTradable Cap9.63BTotal Shares199.00M
T/O5.05MT/O Rate0.05%Tradable Shares153.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Leads Biolabs-B (09887) Schedules 27 Mar 2026 Board Meeting to Approve FY 2025 Results and Consider Dividend
Bulletin Express  ·  03-17 16:43
Leads Biolabs-B (09887) Schedules 27 Mar 2026 Board Meeting to Approve FY 2025 Results and Consider Dividend
Nanjing Leads Biolabs to hold board meeting on annual results and dividend proposal
Reuters  ·  03-17 16:31
Nanjing Leads Biolabs to hold board meeting on annual results and dividend proposal
Leads Biolabs doses first ESCC patient in Phase II Opamtistomig trial
Reuters  ·  03-09
Leads Biolabs doses first ESCC patient in Phase II Opamtistomig trial
Nanjing Leads Biolabs Joins Hang Seng Composite Index, Stock Connect List
MT Newswires Live  ·  03-09
Nanjing Leads Biolabs Joins Hang Seng Composite Index, Stock Connect List
LEADS BIOLABS-B Surges Over 8% in Early Trading, Officially Added to Southbound Trading List
Deep News  ·  03-09
LEADS BIOLABS-B Surges Over 8% in Early Trading, Officially Added to Southbound Trading List
LEADS BIOLABS-B Surges Over 8% on Inclusion in Stock Connect and Clinical Trial Milestone
Stock News  ·  03-09
LEADS BIOLABS-B Surges Over 8% on Inclusion in Stock Connect and Clinical Trial Milestone
LEADS BIOLABS-B to Join Hang Seng Composite Index and Become Eligible for Southbound Trading
Deep News  ·  03-08
LEADS BIOLABS-B to Join Hang Seng Composite Index and Become Eligible for Southbound Trading
LEADS BIOLABS-B (09887) Announces Inclusion in Hang Seng Composite Index and Southbound Trading Link
Bulletin Express  ·  03-06
LEADS BIOLABS-B (09887) Announces Inclusion in Hang Seng Composite Index and Southbound Trading Link
LEADS BIOLABS-B (09887) Included in Hang Seng Composite Index and Added to Stock Connect List
Stock News  ·  03-06
LEADS BIOLABS-B (09887) Included in Hang Seng Composite Index and Added to Stock Connect List
Nanjing Leads Biolabs Joins Hang Seng Composite IndexNanjing Leads Biolabs Co., Ltd. said its shares will be added to the Hang Seng Composite Index effective March 9, 2026, and will also be included in the Stock Connect Southbound Trading Link eligible list
Reuters  ·  03-06
Nanjing Leads Biolabs Joins Hang Seng Composite IndexNanjing Leads Biolabs Co., Ltd. said its shares will be added to the Hang Seng Composite Index effective March 9, 2026, and will also be included in the Stock Connect Southbound Trading Link eligible list
LEADS BIOLABS-B (Stock Code: 09887) Announces First Patient Enrolled in Phase II Trial for Opamtistomig in First-Line Esophageal Squamous Cell Carcinoma
Bulletin Express  ·  03-06
LEADS BIOLABS-B (Stock Code: 09887) Announces First Patient Enrolled in Phase II Trial for Opamtistomig in First-Line Esophageal Squamous Cell Carcinoma
LEADS BIOLABS-B (09887): First Patient Enrolled in Phase II Trial for VELISIN™ in First-Line Esophageal Squamous Cell Carcinoma
Stock News  ·  03-06
LEADS BIOLABS-B (09887): First Patient Enrolled in Phase II Trial for VELISIN™ in First-Line Esophageal Squamous Cell Carcinoma
Nanjing Leads Biolabs Enrolls First Patient in Phase II ESCC Trial of LBL-024
Reuters  ·  03-06
Nanjing Leads Biolabs Enrolls First Patient in Phase II ESCC Trial of LBL-024
Nanjing Leads Biolabs (09887) Releases February 2026 Monthly Return
Bulletin Express  ·  03-03
Nanjing Leads Biolabs (09887) Releases February 2026 Monthly Return
LEADS BIOLABS-B Shares Surge 6% in Afternoon Session on Potential Inclusion in Southbound Trading Scheme
Deep News  ·  02-23
LEADS BIOLABS-B Shares Surge 6% in Afternoon Session on Potential Inclusion in Southbound Trading Scheme
LEADS BIOLABS-B Shares Surge Over 8% in Morning Session on Inclusion in Key Index
Deep News  ·  02-16
LEADS BIOLABS-B Shares Surge Over 8% in Morning Session on Inclusion in Key Index
LEADS BIOLABS-B (09887) Administers First Dose in Phase Ib/II Trial of Velesin™ for Recurrent or Metastatic Triple-Negative Breast Cancer
Stock News  ·  02-10
LEADS BIOLABS-B (09887) Administers First Dose in Phase Ib/II Trial of Velesin™ for Recurrent or Metastatic Triple-Negative Breast Cancer
Nanjing Leads Biolabs (9887) Announces First Patient Dosed in Phase Ib/II Trial of LBL-024 (Opamtistomig) for Recurrent or Metastatic TNBC
Bulletin Express  ·  02-10
Nanjing Leads Biolabs (9887) Announces First Patient Dosed in Phase Ib/II Trial of LBL-024 (Opamtistomig) for Recurrent or Metastatic TNBC
Nanjing Leads Biolabs startet Phase-Ib/II-Studie mit LBL-024 bei triple-negativem Brustkrebs
Reuters  ·  02-10
Nanjing Leads Biolabs startet Phase-Ib/II-Studie mit LBL-024 bei triple-negativem Brustkrebs
LEADS BIOLABS-B Surges Over 9% in Afternoon Trading as TCE Bispecific Antibody LBL-034 Receives FDA Fast Track Designation
Deep News  ·  01-30
LEADS BIOLABS-B Surges Over 9% in Afternoon Trading as TCE Bispecific Antibody LBL-034 Receives FDA Fast Track Designation

Introduction

Company Name.
LEADS BIOLABS-B
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Nanjing Leads Biolabs Co Ltd is a China-based company primarily engaged in the discovery, development, and commercialization of new therapies in oncology, autoimmune, and other severe diseases. The Company’s main drug candidates include LBL-024, LBL-034, LBL-033, LBL-007 and others. The company's LBL-024 is mainly used to treat extra-pulmonary neuroendocrine carcinoma (EP-NEC), small cell lung cancer (SCLC), biliary tract carcinoma (BTC), non-small-cell lung cancer (NSCLC), esophageal squamous cell carcinoma (ESCC), hepatocellular carcinoma (HCC), gastric cancer (GC) and other solid tumors. The Company has also developed multiple proprietary technology platforms, including LeadsBod platform (a CD3 T-cell engager platform), X-body platform (a 4-1BB engager platform) and several other bispecific antibody and fusion protein platforms. The Company mainly conducts its business in the domestic market.
Issue price:
--